eGenesis was founded in 2015 by CRISPR and genomics pioneers, Drs. Luhan Yang and George Church. Recognizing the tremendous unmet demand for transplant organs, eGenesis’ mission is to deliver safe and effective human transplantable cells, tissue and organs utilizing the latest advancements in genome editing.
The company is solely focused on developing a platform using xenotransplantation – the process of grafting or transplanting organs or tissues between members of different species – leveraging advanced genome editing tools.
Our ability to be successful would make a potentially significant impact on the thousands of patients waiting for organ transplants.